Drug Profile
Zidovudine nanoparticles - Valerio Therapeutics
Alternative Names: Zidovudine-TransdrugLatest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator BioAlliance Pharma
- Developer Valerio Therapeutics
- Class Antiretrovirals; Azides; Nucleosides; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 04 Sep 2014 Discontinued - Preclinical for HIV infections in France (PO)
- 21 Feb 2007 Preclinical development is ongoing
- 28 May 2005 Preclinical trials in HIV infections treatment in France (PO)